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Applying diagnosis support systems in
electronic health records to identify
wild-type transthyretin amyloid
cardiomyopathy risk
Connor Willis1 , Alexandre H Watanabe1 , Justin Hughes2 , Kimberly Nolen*,3 , Jason
O’Meara3 , Alexander Schepart3 , Marianna Bruno3 , Joseph Biskupiak1 , Kensaku Kawamoto4 ,
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Aim: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is frequently misdiagnosed, and
delayed diagnosis is associated with substantial morbidity and mortality. At three large academic medical
centers, combinations of phenotypic features were implemented in electronic health record (EHR)
systems to identify patients with heart failure at risk for ATTRwt-CM. Methods: Phenotypes/phenotype
combinations were selected based on strength of correlation with ATTRwt-CM versus non-amyloid heart
failure; different clinical decision support and reporting approaches and data sources were evaluated on
Cerner and Epic EHR platforms. Results: Multiple approaches/sources showed potential usefulness for
incorporating predictive analytics into the EHR to identify at-risk patients. Conclusion: These preliminary
findings may guide other medical centers in building and implementing similar systems to improve
recognition of ATTRwt-CM in patients with heart failure.
First draft submitted: 30 September 2021; Accepted for publication: 13 January 2022; Published online:
31 January 2022
Keywords: amyloidosis • artificial intelligence • cardiomyopathy • diagnosis • electronic health record • heart failure

• machine learning • screening • transthyretin

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease associated with an increased
risk of heart failure and other cardiac and noncardiac abnormalities; gradual worsening in physical function and
health-related quality of life; and elevated rates of hospitalization, morbidity and mortality [1–5]. The disease is
most frequently acquired through age-related aggregation of wild-type transthyretin (TTR) protein, but it may
also be inherited as a TTR gene variant [6,7]. The diagnosis of wild-type ATTR-CM (ATTRwt-CM) poses a
considerable challenge for patients, clinicians and healthcare organizations, with frequent misdiagnosis and delays
in its recognition [8,9]. In a large, prospective, observational study of patients with ATTRwt-CM, the median
diagnostic delay was 39 months, and 42% of patients waited more than 4 years after the presentation of cardiac
symptoms for a diagnosis [5]. Delayed ATTR-CM diagnosis can lead to unnecessary consultations, testing and
treatment prior to diagnosis, as well as more advanced disease at diagnosis [10,11].
Recognition of the potential underdiagnosis of ATTR-CM and substantial disease burden, along with the
current availability of disease-modifying, TTR-stabilizing therapy, has highlighted the need for improved screening
to facilitate early diagnosis [2,9,12,13]. Recent reports of diagnostic algorithms and expert recommendations have
increased awareness of the constructive use of diagnostic “red flags” to prompt suspicion of ATTRwt-CM and
noninvasive imaging techniques to effectively screen at-risk patients [9,14–17]. Current consensus recommendations
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indicate that a noninvasive diagnosis can be reached in select patients with suspected disease based on characteristic
echocardiography/cardiac magnetic resonance findings, Grade 2/3 myocardial uptake of radiotracer on bone
scintigraphy and exclusion of clonal dyscrasia on appropriate serum and urine tests [18]. However, additional work
is required to shorten the diagnostic odyssey of patients with this now treatable but debilitating disease.
In patients with ATTRwt-CM, clinical manifestations, such as arrhythmia, conduction system disease and
carpal tunnel syndrome, may develop several years before the onset of heart failure [7,19,20], providing clues for
ATTR-CM that can aid earlier diagnosis and treatment [9]. However, clinical decision support (CDS) systems
or reporting tools incorporating these clinical manifestations have not yet been developed or implemented to
enhance the screening of patients at risk for ATTRwt-CM. As an initial step in addressing this problem, researchers
developed and validated a Random Forest-based machine-learning (ML) risk-prediction model for ATTRwt-CM
using administrative medical claims data, creating a systematic framework to raise suspicion of potential ATTRwtCM in patients with heart failure [21]. This model was shown to identify ATTRwt-CM in patients with heart failure
with high sensitivity, specificity and accuracy in a large, nationally representative database (87%, 87% and 87%,
respectively [IQVIA, NC, USA]). As summarized in the following report, the authors advanced this foundational
research by implementing adapted algorithms at the point of care. The authors describe how the adapted versions
were implemented in EHRs through a series of pilot studies, with the goal of establishing a resource that enables
the systematic screening of patients with heart failure who are at risk for this form of amyloid disease.
Methods
The original ATTR-CM Random Forest prediction model

A Random Forest ML classifier was created to determine the clinical features associated with ATTRwt-CM versus
non-amyloid heart failure [21]. The model was derived using International Classification of Diseases 9 and 10 (ICD9, ICD-10) diagnosis codes in US medical claims data sourced from IQVIA and validated in IQVIA nationally
R
EHR data–based cohorts. The cohorts included patients
representative medical claims–based and OPTUM
50 years of age or older with diagnosis codes for ATTRwt-CM and heart failure (cases) and patients matched
for age, sex, duration of medical history and number of healthcare visits with codes for heart failure but not for
amyloidosis or amyloid-related conditions (controls). All ICD-9 and ICD-10 codes found in ≥2% of patients
with ATTRwt-CM in the IQVIA medical claims data were used as potential predictive features for this Random
Forest model; one or more related ICD codes were combined into distinct phenotypes using a phenotype grouping
system.
The original Random Forest model performed well in identifying ATTRwt-CM in the heart failure populations,
with sensitivity, specificity and accuracy of 87%, 87% and 87% in IQVIA medical claims data and 90%, 79% and
84% in the OPTUM EHR data [21]. The algorithm also subsequently demonstrated consistent performance when
tested in similarly defined cases and controls using retrospective external real-world EHR datasets from two large
academic medical centers [22].
Adapted ML model design & implementation in pilot studies

Pilot study aim & sites
From the previously developed Random Forest model, the authors created and piloted adaptations within EHRbased CDS and reporting systems with the aim of establishing pragmatic and replicable approaches for medical center
staff to use in identifying patients at high risk for ATTRwt-CM. As described below, the authors scaled down the
original Random Forest model by selecting high-performing phenotypes and phenotype combinations and tested the
adapted versions in three distinct pilot studies. The programs were conducted at academic medical institutions with
specialized multidisciplinary amyloidosis centers and large patient databases located in the eastern, midwestern and
western US: MedStar Health (Baltimore/Washington, DC, metropolitan area); Washington University (WashU)
School of Medicine and affiliated hospitals/clinics (MO, USA); and University of Utah Health (UUH; UT, USA).
Patient criteria & phenotypes/phenotype combinations
In these pilot studies, the authors captured and compared the number of patients with heart failure who were identified as being at risk for ATTRwt-CM based on patient criteria and selected phenotypes/phenotype combinations
within different functional EHR designs and different data sources in the EHR. The EHR-based implementation
approaches were developed based on technical and clinical considerations. The two most widely used EHR plat-
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Pilot program

MedStar health

Washington University
in St. Louis school of medicine

University of
Utah health

n = 53,200

n = 45,051

n = 9051

Epic

Epic

Pts with heart failure

Cerner

Platform
Configuration
type

Clinical decision
support system

Specific
configuration
(data sources)

Discern alert
Diagnoses
Billing transaction

Discern analytics
Diagnoses
Billing transaction

BPA
Problem list
Encounter diagnosis
Medical history

Clarity
Problem list
Encounter diagnosis
Medical history
Billing transaction

∼3 weeks
(April 6, 2020
– April 28, 2020)

∼4 years
(January 1, 2016
– November 30, 2019)

∼6 weeks
(February 26, 2020
– April 13, 2020)

∼2 years
(June 3, 2018
– April 13, 2020)

n = 1164*

n = 3312

n = 368

Run duration
(dates)

Pts identified
with ≥1 ATTR-CM
combination
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Reporting tools

Clinical decision
support system

Reporting tools

n = 4006

Reporting
workbench
Problem list†

Reporting tool

SlicerDicer
Problem list
Encounter diagnosis
Medical history
Billing transaction

Clarity
Problem list
Encounter diagnosis
Medical history

∼6 weeks
(February 26, 2020
– April 13, 2020)

∼3 years
(April 13, 2017
– April 13, 2020)

∼1.5 years
(February 21, 2019
– August 21, 2020)

n = 97

n = 11,646‡

n = 1091

Figure 1. Pilot program cohort summaries.
*15,123 alert firings for 2272 unique visits.
† Active or resolved.‡ Includes duplicate patients.
ATTR-CM: Transthyretin amyloid cardiomyopathy; BPA: Best Practice Advisory; dx: Diagnosis; hx: History: pts: Patients.
R
forms in the USA, Cerner
(MO, USA) and Epic (WI, USA), were used for these pilot studies (Cerner at Medstar,
Epic at UUH and WashU).
A series of instructional guides were developed to support the EHR-based CDS and reporting approaches,
incorporating patient inclusion/exclusion criteria and high-performing phenotypes and phenotype combinations
(Table 1). In all three pilot studies, patient criteria were the following: age ≥50 years; presence of diagnostic codes
for heart failure (ICD-10 codes I50; active or resolved); and absence of diagnosis codes for end-stage renal disease
(N18.6) or amyloidosis (E85).
To select high-performing phenotypes and phenotype combinations, the authors compared the strength of
association of the individual phenotypes (from the original Random Forest model [21]) with ATTRwt-CM versus
non-amyloid heart failure using logistic regression analyses. For the adapted models employed in the MedStar and
WashU programs, nine cardiac and noncardiac phenotypes were selected with odds ratios (ORs) in the highest tertile
for prediction of ATTRwt-CM and grouped into 20 phenotype combinations of up to five phenotypes each, based
on ORs and performance characteristics. For the UUH program’s adapted model, 11 top predictive phenotypes were
selected and grouped into 21 phenotype combinations. A set cover algorithm was used to reduce patient overlap
between the combinations, with filtered combinations covering ≥5% of the ATTR-CM population and having an
OR >5.0 for identifying patients with ATTRwt-CM versus non-amyloid heart failure. The clinical combinations
were developed as a set and were not designed to risk-stratify patients by likelihood of an ATTRwt-CM diagnosis.

CDS/reporting tools & data sources
The CDS approaches explored on the Cerner and Epic platforms were Discern Alert and Best Practice Advisory
(BPA), respectively (Figure 1). CDS alerts for patients who satisfied the specified patient and phenotype criteria
were run "silently" in the background to allow assessment of the system’s feasibility and provide information about
the triggers. On the Cerner and Epic platforms, EHR reports were run using Discern Analytics 2.0 (DA2) and
Reporting Workbench™ (RWB), respectively, in the MedStar Health and WashU pilot studies. Also, based on the
available instructional guides, these reporting tools generated and displayed a list of patients who matched the
specified criteria and may therefore be at risk for ATTRwt-CM.
The warehouse reports were based on queries run in the analytical systems at each institution (Cerner: Cerner
Command Language; Epic: Clarity™ and SlicerDicer) and were used to generate a list of patients who satisfied the
phenotype criteria and were at potential risk. No instructional guides were available to assist with development of
the reports, but each pilot study generated its own process based on the logic of the existing instructional guides to
improve understanding of the findings obtained with the other tools.
On the Cerner platform, clinical condition data displayed on the patient problem list is stored in two separate
tables (problem and diagnosis) (Figure 1), but only one (diagnosis) was employed in the Medstar pilot study. The
Medstar Cerner diagnoses data source included billing transactions. On the Epic platform at WashU, three different

future science group

www.futuremedicine.com

369

370

Future Cardiol. (2022) 18(5)
• Cardiac-related phenotypes
1. Atrial fibrillation/flutter
2. Cardiomegaly
3. Heart block
4. Systolic or combined heart failure
5. Diastolic heart failure
• Noncardiac-related phenotypes
6. Carpal tunnel syndrome
7. CKD
8. Joint disorder
9. Osteoarthrosis
10. Pleurisy or pleural effusion
11. Soft tissue disease†

• Cardiac-related phenotypes
1. Atrial fibrillation/flutter
2. Cardiomegaly
3. Heart block
• Noncardiac-related phenotypes
4. Carpal tunnel syndrome
5. CKD
6. Joint disorder
7. Osteoarthrosis
8. Pleurisy or pleural effusion
9. Soft tissue disease†

Phenotypes

• Atrial fibrillation/flutter plus:
1. Cardiomegaly + joint disorder + systolic or combined heart failure
2. Cardiomegaly + soft tissue disease + diastolic heart failure
3. CKD + pleurisy or pleural effusion + osteoarthrosis + soft tissue disease
4. CKD + pleurisy or pleural effusion + soft tissue disease + diastolic heart failure
5. Heart block + CKD + pleurisy or pleural effusion + systolic or combined heart failure
6. Heart block + CKD + soft tissue disease + systolic or combined heart failure
7. Heart block + joint disorder + osteoarthrosis + soft tissue disease
8. Joint disorder + diastolic heart failure
9. Joint disorder + pleurisy or pleural effusion + systolic or combined heart failure
• Cardiomegaly plus:
10. Joint disorder + diastolic heart failure
11. Joint disorder + soft tissue disease + systolic or combined heart failure
• Heart block plus:
12. Cardiomegaly + diastolic heart failure
13. Cardiomegaly + joint disorder
14. CKD + diastolic heart failure
15. CKD + pleurisy or pleural effusion + soft tissue disease + systolic or combined heart failure
16. Joint disorders + systolic or combined heart failure
17. Soft tissue disease + diastolic heart failure
• Systolic or combined heart failure plus:
18. Diastolic heart failure
• Carpal tunnel syndrome plus:
19. – ‡
• Joint disorder plus:
20. Osteoarthrosis + pleurisy or pleural effusion + diastolic heart failure
21. Osteoarthrosis + pleurisy or pleural effusion + systolic or combined heart failure

• Atrial fibrillation/flutter plus:
1. Cardiomegaly + CKD + joint disorder
2. Cardiomegaly + CKD + joint disorder + osteoarthrosis
3. Cardiomegaly + CKD + soft tissue disease
4. Cardiomegaly + joint disorder + soft tissue disease
5. Cardiomegaly + joint disorder + osteoarthrosis + pleurisy or pleural effusion
6. Carpal tunnel syndrome
7. Heart block + cardiomegaly + osteoarthrosis
8. Heart block + joint disorder
• Cardiomegaly plus:
9. Carpal tunnel syndrome
10. CKD + joint disorder + soft tissue disease
11. Joint disorder + osteoarthrosis + pleurisy or pleural effusion
• Heart block plus:
12. Cardiomegaly + CKD + osteoarthrosis
13. Cardiomegaly + joint disorder
14. Cardiomegaly + joint disorder + osteoarthrosis
15. Cardiomegaly + soft tissue disease
16. CKD + joint disorder
17. Joint disorder + osteoarthrosis
18. Joint disorder + soft tissue disease
• Carpal tunnel syndrome plus:
19. – ‡
20. CKD

Phenotype combinations

future science group

‡ Combined

enthesopathy, non-traumatic tendon rupture and strains or sprains.
with patient inclusion criteria.
ATTR-CM: Transthyretin amyloid cardiomyopathy; CKD: Chronic kidney disease; EHR: Electronic health record; UUH: University of Utah Health; WashU: Washington University.

† Includes

• Age ≥50 years
• Heart failure diagnosis (active/resolved)
• No end-stage renal disease diagnosis
• No amyloidosis diagnosis, that is, none of the following:
◦ Light-chain amyloidosis
◦ Cerebral amyloid angiopathy
◦ Amyloidosis/other amyloidosis/unspecified amyloidosis
◦ Secondary systemic amyloidosis
◦ Organ-limited amyloidosis
◦ Wild-type transthyretin–related amyloidosis
◦ Non-neuropathic/neuropathic/unspecified heredofamilial
amyloidosis

UUH (Epic) pilot program

• Age ≥50 years
• Heart failure diagnosis (active/resolved)
• No end-stage renal disease diagnosis
• No amyloidosis diagnosis, that is, none of the following:
◦ Light-chain amyloidosis
◦ Cerebral amyloid angiopathy
◦ Amyloidosis/other amyloidosis/unspecified amyloidosis
◦ Secondary systemic amyloidosis
◦ Organ-limited amyloidosis
◦ Wild-type transthyretin–related amyloidosis
◦ Non-neuropathic/neuropathic/unspecified heredofamilial
amyloidosis

Medstar (Cerner) and WashU (Epic) pilot programs

Patient criteria

Table 1. Patient criteria and ATTRwt-CM–associated phenotypes/phenotype combinations implemented in the EHR-based pilot programs.
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EHR diagnosis data sources (problem list, encounter diagnosis and medical history) and one non-EHR diagnosis
data source (billing transactions) were evaluated separately for functional quality, although these data sources were
not available for all CDS and reporting tools. An iterative process was followed for development and testing, so
that the authors could better understand the technical, operational and clinical steps needed to integrate the CDS
and reporting tools into each EHR system.

Results
All the CDS and reporting tools on the Cerner and Epic platforms were successfully implemented to provide
a framework supporting the identification of patients at risk for ATTRwt-CM. Patients included in the at-risk
heart failure cohorts and patients identified by the adapted algorithms platform are summarized in Figure 1 by
pilot program, platform, configuration and data source. A quantitative comparative analysis of the outputs across
programs and configurations was not conducted to detect differences due to variability among the datasets. Each
tool (and data source) yielded different counts of at-risk patients in part due to differences in data documentation
completeness and data retrieval time frames. Because the pilot studies were conducted at specialized amyloidosis
centers, differences in patient referral patterns may also have contributed to differences in data completeness.
These constraints, which may have limited the number of at-risk patients identified using some tools, warrant
consideration as additional institutions seek to implement ATTR-CM phenotype algorithms into live Cerner or
Epic environments in the future.
The most commonly found phenotype combinations associated with ATTRwt-CM in the heart failure cohorts
across the three pilot studies are shown in Figure 2 [23,24].

Discussion
Strengths & limitations

The strengths and limitations of the original Random Forest model have been previously summarized [21]. Like the
original model, the current adapted algorithm was developed to predict patients at risk for ATTRwt-CM using
ICD codes readily available in the EHR. These codes represent the international language of medical diagnoses and
are easy to use in the EHR setting. However, conditions documented in patient charts by means other than ICD
code (e.g., textual description of echocardiographic findings) were not captured in the algorithm.
On the Cerner platform, the Discern Alert tool was used to identify patients in real time. However, because the
tool triggers only during an interaction with a patient’s chart and stops evaluation after finding a single phenotype
combination match, further analysis was often needed to obtain the complete clinical profile. In the authors’
experience, the DA2 report was the most comprehensive of the Cerner tools, as it allowed for the longest search
interval. The disadvantages of this tool included common performance and timeout issues and its capacity to run
only one phenotype combination at a time, which required a greater manual workload to reconcile duplicates.
On the Epic platform, based on their design, BPAs had the advantage of identifying at-risk patients in real time,
but these only included patients with an active encounter at the time of the alert. In addition, some diagnosis data
sources (e.g., billing transactions) within the system were not available for use as criteria in the BPA logic as it was
built in the instructional guides.
The RWB is an operational report for identifying patients in shorter time windows (e.g., 2 weeks or a month),
serving as a useful option for clinical care but having limited value in other, broader applications. Because the RWB
report was implemented within the EHR, it was run for only a single amyloid specialist provider for the specified
period; it could also only be implemented using the problem list data source.
The authors found the Epic Clarity report to be very comprehensive, allowing for the longest search period and
most diagnosis data sources. Because of the substantial amount of data gathered, the Clarity reports may require a
considerable amount of time to run, but the system did not demonstrate anticipated performance issues with any
report configuration.
Finally, SlicerDicer is also only intended to process simple queries and is not capable of scaling complex combinations. Following the authors’ approach, SlicerDicer allowed only one phenotype combination to be implemented
at a time, which resulted in a greater manual workload to avoid duplication. An additional consideration is that
SlicerDicer presents data at the population level, not the patient level.
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MedStar

No. of pts
identified at risk

Phenotype combination associated with wild-type ATTR-CM

41

Heart block+joint disorder+OA

40

Afib+heart block+joint disorder
Heart block+CKD+joint disorder
26

859

17

Heart block+joint disorder+soft tissue disease

557

10

Carpal tunnel syndrome+CKD
0

331
20
30
Patients (%)

10

40

Washington University

50

No. of pts
identified at risk

Phenotype combination associated with wild-type ATTR-CM

12

Afib+cardiomegaly+CKD+joint disorder
Afib+cardiomegaly+CKD+soft tissue disease

487
664

17

Afib+heart block+cardiomegaly+OA

958

24
15

Afib+heart block+joint disorders
Cardiomegaly+joint disorder+OA+pleurisy/pleural effusion

582
407

10

Heart block+cardiomegaly+CKD+OA

20

815

15

Heart block+cardiomegaly+joint disorder

604
453

11

Heart block+cardiomegaly+joint disorder+OA

786

20

Heart block+cardiomegaly+soft tissue disease
12

Heart block+CKD+joint disorder

484
21

Heart block+joint disorder+OA
Carpal tunnel syndrome

829
25

0

1326
1071

32

Carpal tunnel syndrome

1362

10

1006
30

20
Patients (%)

University of Utah health
No. of pts
identified at risk

Phenotype combination associated with wild-type ATTR-CM

49

Systolic or combined HF+diastolic HF

Carpal tunnel syndrome

340

31

18

Afib+joint disorder+diastolic HF

0

537

196

20

40

60

Patients (%)

Figure 2. Proportion of patients identified as at risk in the reports at Medstar (Cerner, Discern Analytics),
Washington University (Epic, Clarity) and University of Utah Health (Epic, Clarity) by ATTRwt-CM-related phenotype
combination found in ≥10% of patients.
Afib: Atrial fibrillation; ATTR-CM: Transthyretin amyloid cardiomyopathy; CKD: Chronic kidney disease; HF: Heart
failure; OA: Osteoarthritis; pts: Patients.
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Ad hoc & recommended modifications

In the pilot studies, some modifications to the instructional guides were recommended to improve usability and
achieve other important learnings that may help guide other organizations in the future. At Medstar Health, for
the Cerner platform CDS and reports, the authors updated the instructions to use diagnoses instead of problems
because diagnoses were more comprehensive (e.g., they may have included billing diagnoses). Because patient lists
“timed out” or took several minutes to run, the authors scheduled reports to run automatically or to use run-time
prompts to add additional filters, which reduced the time necessary for staff to receive and review results. The
authors also modified build-step sequencing to reduce overall configuration time. Finally, when using Cerner, they
observed that the CDS alert fired only for the first qualifying phenotype combination; as a result, training materials
for future users should note the need for organizations to review patients’ complete charts and list combinations.
In the Epic platform, because conditions were recorded in multiple sources and in different ways across these
sources, the authors recommend that future users evaluate existing diagnosis and problem documentation practices
before selecting the sources. For example, because clinicians in healthcare institutions generally do not maintain a
complete and accurate problem list, the inclusion of visit diagnoses in the phenotyping process may be advisable.
Future users may also choose to examine the feasibility of using billing diagnoses, as these data sources appear to
yield the most accurate results. In keeping with its design, the RWB tool timed out when run over long periods and
when many patients/groups were included; however, the authors were able to handle this challenge by narrowing
the search criteria, such as by querying for one physician, one location or a shorter time interval.
When following their build approach on the Epic platform, the authors noted that the BPA tool did not
dynamically display the combination triggering notification, requiring all relevant diagnoses to be listed in the
notification window and/or clear language used in the notification. However, future users may overcome these
R
International CDS Hooks specification [25],
technical obstacles by using a services-based approach such as the HL7
which enables the generation of dynamic CDS messages. The use of CDS Hooks can allow for increasing numbers
of patient problems and diagnoses without requiring a higher level of effort from healthcare organization staff, as
the algorithms used to process the diagnoses are encoded by the CDS Hooks service provider rather than configured
by the local healthcare system.
The authors acknowledge that other approaches could have been implemented in these pilot studies to achieve
the aim of identifying patients at risk of ATTRwt-CM. For example, in the future, Cerner users may consider
using the programmable population health management platform HealtheIntent, whereas Epic users may consider
additional tools such as registries and programs that enable Clarity-based insights to be incorporated back into
the EHR and leveraged within the RWB platform. Moreover, as mentioned, researchers may also choose to follow
standards-based approaches such as CDS Hooks for future initiatives.
Conclusion
In these pilot studies, the authors found that predictive phenotype combinations associated with ATTRwt-CM can
be successfully implemented using EHR-based tools to identify patients with heart failure at risk for the disease.
While encouraged by the numbers of patients with suspected disease “flagged” with these comprehensive screening
approaches (although the patient lists were not verified), additional work is needed to help develop a multistep
approach and enhance implementation resources that can be used to identify patients with heart failure who are
most in need of ATTRwt-CM screening in clinical practice and healthcare systems.
Future perspective
ATTRwt-CM is very difficult to identify in patients with heart failure in part due to the number of other, more
common possible etiologies of their disease. However, advances in ML technology and greater availability of patient
data are enabling computational solutions to this diagnostic challenge. We adapted and implemented a Random
Forest model for identifying patients in the EHR who met prespecified criteria associated with ATTRwt-CM.
Although successful, further refinement and investigation are required to achieve more workable approaches that
will result in broader adoption. For example, we suggest that further risk stratification (e.g., inclusion of patients
>60 years of age) or other modifications be considered to ensure that the estimated workload can be managed
with allocated staffing resources. In future research, we also plan to assess performance metrics of the phenotype
combinations used in our pilot studies by calculating the frequency of confirmatory diagnoses observed in a sample
of patients identified as being at risk. Over time, as the tools’ clinical usefulness improves and they are adopted
more widely, their use may lead to important changes in routine evaluation procedures followed for patients
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with suspected cardiac amyloid disease, such as less reliance on echo-/electrocardiographic findings and invasive
tissue biopsy, which could help to shorten and simplify patients’ diagnostic odyssey. Finally, importantly, while the
current research focused specifically on ATTRwt-CM, we believe our approaches will likely prove scalable to other
difficult-to-diagnose, rare diseases.
Summary points
• Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is a progressive, life-threatening disease and a
frequently underrecognized cause of heart failure in older patients; it is often misdiagnosed or diagnosed late in
the disease course, as patients’ heart failure is attributed to more common causes such as hypertension or renal
disease.
• Several cardiac and noncardiac clinical manifestations are known to be “red flags” for ATTRwt-CM, developing
several years prior to heart failure onset in many patients. However, to date, no clinical decision support (CDS) or
reporting tools have been developed incorporating these clinical clues to improve screening and identification of
patients with the disease.
• As reported here, in pilot studies conducted at three large academic medical institutions, the classifier of a
previously developed and validated Random Forest machine learning risk-prediction model for ATTRwt-CM was
judiciously adapted and implemented into multiple electronic health record CDS and reporting systems.
• After selected patient criteria and phenotypes/phenotype combinations were implemented using different data
sources and different electronic health record–based CDS and reporting tools on Cerner and Epic platforms, the
numbers of patients with heart failure identified as at risk for ATTRwt-CM were compared.
• All approaches showed potential usefulness in identifying patients at risk for ATTRwt-CM, but a quantitative
comparison of their yield was not conducted due to variability among datasets, related to differences in data
documentation completeness, data collection time frames and patient referral patterns.
• The phenotypes/phenotype combinations most often associated with ATTRwt-CM in patients with heart failure in
the three pilot studies included carpal tunnel syndrome; heart block plus joint disorders plus osteoarthritis; heart
block plus chronic kidney disease plus joint disorders; atrial fibrillation plus heart block plus joint disorders; and
atrial fibrillation plus heart block plus cardiomegaly plus osteoarthritis.
• Based on the pilot program experiences, each approach had strengths and limitations that will require
consideration with future use, including the potential need for ad hoc modifications to overcome obstacles
encountered at the time of implementation.
• Additional work is under way to refine the approaches piloted at these medical centers and to further examine
their usefulness and applicability in clinical practice and healthcare system settings.
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